BRPI0515553A - formulações lìquidas estáveis de dna de plasmìdeo - Google Patents

formulações lìquidas estáveis de dna de plasmìdeo

Info

Publication number
BRPI0515553A
BRPI0515553A BRPI0515553-3A BRPI0515553A BRPI0515553A BR PI0515553 A BRPI0515553 A BR PI0515553A BR PI0515553 A BRPI0515553 A BR PI0515553A BR PI0515553 A BRPI0515553 A BR PI0515553A
Authority
BR
Brazil
Prior art keywords
plasmid dna
stable
dna
relates
present
Prior art date
Application number
BRPI0515553-3A
Other languages
English (en)
Inventor
Francis Blanches
Michel Coudert
Nicolas Maestrall
Thierry Guillemin
David Gaillac
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Centelion filed Critical Centelion
Publication of BRPI0515553A publication Critical patent/BRPI0515553A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"FORMULAçõES LìQUIDAS ESTáVEIS DE DNA DE PLASMìDEO". A presente invenção refere-se à formulações líquidas de DNA de plasmídeo que são estáveis e permanecem não degradadas a +4<198>C a temperatura ambiente durante longos períodos de tempo e são, assim, úteis para armazenamento de DNA de plasmídeo que é usado para pesquisa, terapia baseada em plamídeo, tal como vacina de DNA e terapia genética. A presente invenção também refere-se a um método de conservação de DNA de plasmídeo em uma forma estável ao longo do tempo a +4<198>C a temperatura ambiente. A presente invenção também refere-se a composições estáveis líquidas de DNA de plasmídeo para uso em um método de tratamento do corpo de um ser humano ou animal através de terapia baseada em plasmídeo, tal como vacinação com DNA ou terapia genética.
BRPI0515553-3A 2004-09-17 2005-09-19 formulações lìquidas estáveis de dna de plasmìdeo BRPI0515553A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
BRPI0515553A true BRPI0515553A (pt) 2008-07-29

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515553-3A BRPI0515553A (pt) 2004-09-17 2005-09-19 formulações lìquidas estáveis de dna de plasmìdeo

Country Status (14)

Country Link
EP (1) EP1791945A1 (pt)
JP (1) JP2008512997A (pt)
KR (1) KR20070058621A (pt)
CN (1) CN101040041A (pt)
AU (1) AU2005284244A1 (pt)
BR (1) BRPI0515553A (pt)
CA (1) CA2579340A1 (pt)
EA (1) EA011554B1 (pt)
IL (1) IL181753A0 (pt)
MX (1) MX2007003214A (pt)
NO (1) NO20071946L (pt)
NZ (1) NZ553914A (pt)
TN (1) TNSN07087A1 (pt)
WO (1) WO2006029908A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
WO2016108264A1 (ja) * 2014-12-29 2016-07-07 株式会社ボナック 核酸分子を安定に含有する組成物
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
WO2019023937A1 (zh) * 2017-08-01 2019-02-07 深圳华大智造科技有限公司 一种高效的内切酶缓冲液体系
MX2020002124A (es) 2017-08-25 2020-07-20 Zoetis Services Llc Un metodo para inmovilizar una sonda de acido nucleico a un soporte solido.
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
SG11202101113YA (en) * 2018-08-30 2021-04-29 Glaxosmithkline Ip Dev Ltd Methods of detecting nucleic acid
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
KR20230141965A (ko) * 2022-03-24 2023-10-10 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
WO2001043693A2 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef

Also Published As

Publication number Publication date
KR20070058621A (ko) 2007-06-08
NO20071946L (no) 2007-05-29
EP1791945A1 (en) 2007-06-06
CN101040041A (zh) 2007-09-19
MX2007003214A (es) 2007-10-11
EA011554B1 (ru) 2009-04-28
AU2005284244A1 (en) 2006-03-23
JP2008512997A (ja) 2008-05-01
EA200700656A1 (ru) 2007-10-26
IL181753A0 (en) 2007-07-04
WO2006029908A1 (en) 2006-03-23
NZ553914A (en) 2009-11-27
CA2579340A1 (en) 2006-03-23
TNSN07087A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
BRPI0515553A (pt) formulações lìquidas estáveis de dna de plasmìdeo
Eriksson et al. In VivoGene Transfer to Skin and Wound by Microseeding
BRPI0414867A (pt) pirazolopiridinas e seus análogos
BR112015005674A2 (pt) variantes e métodos de uso de hppd
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
BR9914939A (pt) Genes e vetores para conferir resistência a herbicidas em plantas
PT1758860E (pt) 3-piridil-benzocicloalquilmetil-aminas saturadas e insaturadas para utilização no tratamento da dor, depressões e estados de ansiedade
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2004067753A3 (en) Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
BRPI0412902A (pt) compostos contendo imidazo substituìdo por oxima
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
WO2007084247A3 (en) Stable therapeutic formulations
WO2007035213A3 (en) Transgenic ungulates expressing ctla4-ig and uses thereof
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell&#39;epidermide
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
MX2007013298A (es) Metodo para preparar y usar composiciones de feromona esteroide basadas en agua.
DE60028367D1 (de) Oligonukleotide die eine antisense-sequenz enthalten die durch eine sekondärstruktur stabilisiert sind und pharmazeutische zusammensetzungen die sie enthalten
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
RU2013121802A (ru) Профилактический или терапевтический агент для лечения фиброза
ATE552272T1 (de) Myostatin-isoform
HUP0204376A2 (hu) Új invertáz-inhibitorok és alkalmazásuk
PE20080213A1 (es) Derivados del acido fenilacetico como inhibidores de la ciclooxigenasa-2
DK1178960T3 (da) Vitamin D analoger og deres farmaceutiske anvendelse

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.